C
Halozyme Therapeutics, Inc.
HALO
$62.54
-$0.41-0.65%
C
Hold
3/4/2025Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 3/4/2025 due to an increase in the efficiency index, total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 3/4/2025 due to an increase in the efficiency index, total return index and volatility index.
C
Hold
1/13/2025Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 1/13/2025 due to a decline in the total return index, valuation index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 1/13/2025 due to a decline in the total return index, valuation index and volatility index.
C
Hold
12/4/2024Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 12/4/2024 due to a large decline in the total return index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 12/4/2024 due to a large decline in the total return index.
B
Buy
11/19/2024Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 11/19/2024 due to a noticeable increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 11/19/2024 due to a noticeable increase in the total return index.
C
Hold
11/4/2024Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 11/4/2024 due to a noticeable decline in the total return index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 11/4/2024 due to a noticeable decline in the total return index and efficiency index.
B
Buy
10/24/2024Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 10/24/2024 due to a noticeable increase in the total return index, valuation index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 10/24/2024 due to a noticeable increase in the total return index, valuation index and volatility index.
C
Hold
10/8/2024Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 10/8/2024 due to a large decline in the total return index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 10/8/2024 due to a large decline in the total return index.
B
Buy
9/19/2024Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 9/19/2024 due to a major increase in the total return index, volatility index and solvency index. Debt to equity declined from 8.44 to 5.19, and the quick ratio increased from 5.01 to 5.58.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 9/19/2024 due to a major increase in the total return index, volatility index and solvency index. Debt to equity declined from 8.44 to 5.19, and the quick ratio increased from 5.01 to 5.58.
C
Hold
5/20/2024Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 5/20/2024 due to a major increase in the growth index, valuation index and solvency index. Debt to equity declined from 17.97 to 8.44, and operating cash flow increased 26.45% from $102.35M to $129.43M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 5/20/2024 due to a major increase in the growth index, valuation index and solvency index. Debt to equity declined from 17.97 to 8.44, and operating cash flow increased 26.45% from $102.35M to $129.43M.
C
Hold
4/18/2023Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 4/18/2023 due to a major decline in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 4/18/2023 due to a major decline in the total return index and volatility index.
C
Hold
3/16/2023Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 3/16/2023 due to a large decline in the total return index, growth index and volatility index. Total revenue declined 13.15% from $208.98M to $181.5M, EBIT declined 9.3% from $83.69M to $75.91M, and earnings per share declined from $0.44 to $0.4231.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 3/16/2023 due to a large decline in the total return index, growth index and volatility index. Total revenue declined 13.15% from $208.98M to $181.5M, EBIT declined 9.3% from $83.69M to $75.91M, and earnings per share declined from $0.44 to $0.4231.
B
Buy
2/1/2023Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to B- from B on 2/1/2023 due to a decline in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to B- from B on 2/1/2023 due to a decline in the total return index and volatility index.
B
Buy
12/8/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B from B- on 12/8/2022 due to a major increase in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B from B- on 12/8/2022 due to a major increase in the total return index and volatility index.
B
Buy
12/2/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 12/2/2022 due to a large increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 12/2/2022 due to a large increase in the total return index.
C
Hold
11/11/2022Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 11/11/2022 due to a significant decline in the total return index, valuation index and solvency index. Debt to equity increased from 4.26 to 15.53.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 11/11/2022 due to a significant decline in the total return index, valuation index and solvency index. Debt to equity increased from 4.26 to 15.53.
B
Buy
8/18/2022Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to B- from B on 8/18/2022 due to a decline in the growth index, solvency index and total return index. The quick ratio declined from 8.06 to 2, earnings per share declined from $0.43 to $0.16, and EBIT declined 54.99% from $75.67M to $34.06M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to B- from B on 8/18/2022 due to a decline in the growth index, solvency index and total return index. The quick ratio declined from 8.06 to 2, earnings per share declined from $0.43 to $0.16, and EBIT declined 54.99% from $75.67M to $34.06M.
B
Buy
7/28/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B from B- on 7/28/2022 due to a significant increase in the total return index, growth index and solvency index. EBIT increased 33.85% from $56.53M to $75.67M, debt to equity declined from 4.46 to 3.38, and total revenue increased 14.98% from $102M to $117.28M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B from B- on 7/28/2022 due to a significant increase in the total return index, growth index and solvency index. EBIT increased 33.85% from $56.53M to $75.67M, debt to equity declined from 4.46 to 3.38, and total revenue increased 14.98% from $102M to $117.28M.
B
Buy
5/9/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 5/9/2022 due to an increase in the efficiency index, volatility index and total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 5/9/2022 due to an increase in the efficiency index, volatility index and total return index.
C
Hold
2/17/2022Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 2/17/2022 due to a decline in the volatility index, total return index and valuation index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 2/17/2022 due to a decline in the volatility index, total return index and valuation index.
B
Buy
2/2/2022Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 2/2/2022 due to an increase in the total return index, valuation index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 2/2/2022 due to an increase in the total return index, valuation index and efficiency index.
C
Hold
1/18/2022Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 1/18/2022 due to a decline in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 1/18/2022 due to a decline in the total return index and volatility index.
B
Buy
11/4/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 11/4/2021 due to a substantial increase in the valuation index, efficiency index and solvency index. Net income increased 136.82% from $91.46M to $216.59M, debt to equity declined from 7.32 to 3.12, and total capital increased 16.25% from $998.51M to $1.16B.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 11/4/2021 due to a substantial increase in the valuation index, efficiency index and solvency index. Net income increased 136.82% from $91.46M to $216.59M, debt to equity declined from 7.32 to 3.12, and total capital increased 16.25% from $998.51M to $1.16B.
C
Hold
10/14/2021Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 10/14/2021 due to a decline in the volatility index and total return index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C+ from B- on 10/14/2021 due to a decline in the volatility index and total return index.
B
Buy
9/29/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 9/29/2021 due to an increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to B- from C+ on 9/29/2021 due to an increase in the total return index.
C
Hold
8/12/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 8/12/2021 due to a noticeable increase in the valuation index, growth index and solvency index. Earnings per share increased from $0.19 to $0.62, EBIT increased 83.4% from $50.74M to $93.05M, and total revenue increased 53.28% from $89.02M to $136.46M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 8/12/2021 due to a noticeable increase in the valuation index, growth index and solvency index. Earnings per share increased from $0.19 to $0.62, EBIT increased 83.4% from $50.74M to $93.05M, and total revenue increased 53.28% from $89.02M to $136.46M.
C
Hold
5/26/2021Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 5/26/2021 due to a major decline in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 5/26/2021 due to a major decline in the total return index and volatility index.
C
Hold
5/11/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 5/11/2021 due to an increase in the efficiency index, total return index and volatility index. Total capital increased 70.19% from $553.14M to $941.37M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 5/11/2021 due to an increase in the efficiency index, total return index and volatility index. Total capital increased 70.19% from $553.14M to $941.37M.
C
Hold
3/16/2021Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 3/16/2021 due to a major decline in the growth index, total return index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 3/16/2021 due to a major decline in the growth index, total return index and efficiency index.
C
Hold
1/5/2021Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 1/5/2021 due to a noticeable increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 1/5/2021 due to a noticeable increase in the total return index.
C
Hold
12/21/2020Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 12/21/2020 due to a decline in the total return index, volatility index and valuation index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 12/21/2020 due to a decline in the total return index, volatility index and valuation index.
C
Hold
12/3/2020Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 12/3/2020 due to a large increase in the total return index and volatility index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from C on 12/3/2020 due to a large increase in the total return index and volatility index.
C
Hold
11/18/2020Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 11/18/2020 due to a large decline in the total return index, valuation index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C from C+ on 11/18/2020 due to a large decline in the total return index, valuation index and efficiency index.
C
Hold
11/3/2020Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from D+ on 11/3/2020 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 84.7% from $3.29M to $6.08M, net income increased 40.24% from $25.82M to $36.21M, and EBIT increased 36.35% from $29.56M to $40.3M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C+ from D+ on 11/3/2020 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 84.7% from $3.29M to $6.08M, net income increased 40.24% from $25.82M to $36.21M, and EBIT increased 36.35% from $29.56M to $40.3M.
D
Sell
4/2/2020Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 4/2/2020 due to an increase in the total return index and valuation index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 4/2/2020 due to an increase in the total return index and valuation index.
D
Sell
3/17/2020Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 3/17/2020 due to a significant decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.27 to 4.42.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 3/17/2020 due to a significant decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.27 to 4.42.
D
Sell
2/19/2020Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 2/19/2020 due to a noticeable increase in the total return index, growth index and efficiency index. Total revenue increased 18.09% from $39.15M to $46.23M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 2/19/2020 due to a noticeable increase in the total return index, growth index and efficiency index. Total revenue increased 18.09% from $39.15M to $46.23M.
D
Sell
8/7/2019Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 8/7/2019 due to a large decline in the growth index. Earnings per share declined from $0.01 to -$0.1006, EBIT declined 571.24% from $2.97M to -$13.98M, and operating cash flow declined 460.26% from -$4.42M to -$24.79M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 8/7/2019 due to a large decline in the growth index. Earnings per share declined from $0.01 to -$0.1006, EBIT declined 571.24% from $2.97M to -$13.98M, and operating cash flow declined 460.26% from -$4.42M to -$24.79M.
D
Sell
8/5/2019Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 8/5/2019 due to an increase in the volatility index, solvency index and efficiency index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 8/5/2019 due to an increase in the volatility index, solvency index and efficiency index.
D
Sell
5/8/2019Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 5/8/2019 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 142.29% from $10.46M to -$4.42M, total revenue declined 5.45% from $60.23M to $56.95M, and total capital declined 2.62% from $375.27M to $365.45M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 5/8/2019 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 142.29% from $10.46M to -$4.42M, total revenue declined 5.45% from $60.23M to $56.95M, and total capital declined 2.62% from $375.27M to $365.45M.
D
Sell
4/23/2019Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 4/23/2019 due to an increase in the total return index, volatility index and solvency index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D+ from D on 4/23/2019 due to an increase in the total return index, volatility index and solvency index.
D
Sell
2/25/2019Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 2/25/2019 due to a major decline in the efficiency index, valuation index and total return index. Total capital declined 2.83% from $386.2M to $375.27M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D from D+ on 2/25/2019 due to a major decline in the efficiency index, valuation index and total return index. Total capital declined 2.83% from $386.2M to $375.27M.
D
Sell
11/7/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D+ from C- on 11/7/2018 due to a large decline in the valuation index, growth index and efficiency index. Total revenue declined 27.4% from $35.2M to $25.56M, EBIT declined 26.91% from -$20.07M to -$25.47M, and net income declined 21.65% from -$22.89M to -$27.85M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D+ from C- on 11/7/2018 due to a large decline in the valuation index, growth index and efficiency index. Total revenue declined 27.4% from $35.2M to $25.56M, EBIT declined 26.91% from -$20.07M to -$25.47M, and net income declined 21.65% from -$22.89M to -$27.85M.
C
Hold
10/24/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 10/24/2018 due to a decline in the volatility index and total return index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 10/24/2018 due to a decline in the volatility index and total return index.
C
Hold
9/20/2018Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from C- on 9/20/2018 due to an increase in the volatility index, valuation index and solvency index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from C- on 9/20/2018 due to an increase in the volatility index, valuation index and solvency index.
C
Hold
8/8/2018Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C- from D+ on 8/8/2018 due to a major increase in the growth index, efficiency index and valuation index. Earnings per share increased from -$0.1925 to -$0.16, net income increased 16.63% from -$27.46M to -$22.89M, and EBIT increased 15.35% from -$23.71M to -$20.07M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C- from D+ on 8/8/2018 due to a major increase in the growth index, efficiency index and valuation index. Earnings per share increased from -$0.1925 to -$0.16, net income increased 16.63% from -$27.46M to -$22.89M, and EBIT increased 15.35% from -$23.71M to -$20.07M.
D
Sell
8/2/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D+ from C- on 8/2/2018 due to a large decline in the total return index, volatility index and solvency index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D+ from C- on 8/2/2018 due to a large decline in the total return index, volatility index and solvency index.
C
Hold
5/14/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 5/14/2018 due to a substantial decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.8457 to -$0.1925, net income declined 122.17% from $123.88M to -$27.46M, and EBIT declined 118.83% from $125.93M to -$23.71M.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 5/14/2018 due to a substantial decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.8457 to -$0.1925, net income declined 122.17% from $123.88M to -$27.46M, and EBIT declined 118.83% from $125.93M to -$23.71M.
C
Hold
5/10/2018Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from C- on 5/10/2018 due to a noticeable increase in the total return index.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from C- on 5/10/2018 due to a noticeable increase in the total return index.
C
Hold
4/25/2018Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 4/25/2018 due to a large decline in the total return index.
Halozyme Therapeutics, Inc. (HALO) was downgraded to C- from C on 4/25/2018 due to a large decline in the total return index.
C
Hold
2/21/2018Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from D on 2/21/2018 due to a substantial increase in the total return index, efficiency index and valuation index. Net income increased 4,406.44% from $2.75M to $123.88M, and total capital increased 47.08% from $279.24M to $410.72M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to C from D on 2/21/2018 due to a substantial increase in the total return index, efficiency index and valuation index. Net income increased 4,406.44% from $2.75M to $123.88M, and total capital increased 47.08% from $279.24M to $410.72M.
D
Sell
5/11/2016Upgraded
Halozyme Therapeutics, Inc. (HALO) was upgraded to D from D- on 5/11/2016 due to an increase in the efficiency index and total return index. Total capital increased 142.9% from $92.83M to $225.49M.
Halozyme Therapeutics, Inc. (HALO) was upgraded to D from D- on 5/11/2016 due to an increase in the efficiency index and total return index. Total capital increased 142.9% from $92.83M to $225.49M.
D
Sell
3/11/2016Downgrade
Halozyme Therapeutics, Inc. (HALO) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.95 to 2.25.
Halozyme Therapeutics, Inc. (HALO) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.95 to 2.25.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
